Janux Therapeutics (JANX) Stock: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$18.39
-0.11 (-0.59%)
âŧ
5d:
+8.62%
30d:
+4.02%
90d:
+13.94%
WAIT
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 05, 2026
25d
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: JANX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: JANX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $18.39, which is considered slightly high relative to its 30-day fair value range of $16.43 to $18.83.
Technical Outlook: Technically, JANX is in a strong uptrend. Immediate support is located at $16.13, while resistance sits at $19.18.
Market Sentiment: JANX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.24 (+97.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JANX is in a strong uptrend. Immediate support is located at $16.13, while resistance sits at $19.18.
Market Sentiment: JANX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.24 (+97.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$16.43 -
$18.83
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 97.0% below Wall St target ($36.24)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.43 -
$18.83
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$16.13
Resistance Level
$19.18
Current Trend
Strong Uptrend
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.01
Wall Street Target
$36.24
(+97.0%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: October 10, 2026 12:04 PM ET
Data refreshes hourly during market hours. Next update: 1:04 PM
Data refreshes hourly during market hours. Next update: 1:04 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$198 | 51 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$110 | 67 BUY |
|
CGON
CG Oncology, Inc. CommonâĻ |
STRONG BUY
15 analysts |
$91 | 70 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$682 | 43 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 57 HOLD |
